Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03879213
Other study ID # IRB2018-046
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 17, 2018
Est. completion date June 1, 2020

Study information

Verified date July 2020
Source Clinical Nutrition Research Center, Illinois Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are:

1. Evaluate the effects of acute dietary raspberry intake on metabolic-associated impairments in cognitive and psychomotor function in overweight/obese adults (55-70y) following a meal challenge

2. Evaluate the effects of acute dietary raspberry on measures of vascular function.


Description:

The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening.

This multi-center clinical trial is a randomized, single-blind, 2-arm, placebo-controlled, within subject cross-over trial, featuring a repeated postprandial sampling paradigm to evaluate the effects of acute dietary red raspberry intake on cognitive function, inflammation, insulin sensitivity / glucose handling and vascular function in overweight/obese older adults after consuming a standardized challenge meal.

A planned sample size of 30 will be enrolled into the study. This study will require one initial screening visit and 3 study visits. This study will take approximately 3-4 weeks per subject to complete.

The initial screening visit will provide subject with their site-specific, IRB-approved informed consent document prior to the start of any study related procedures. Subject eligibility will be determined through anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey relate to general eating, health, mood and exercise habits.

Eligible subjects will follow a limited polyphenolic diet throughout the duration of their participation, although stricter guidelines will be imposed during the 3 days prior to a study visit. Shopping lists and meal plans will be provided to subjects, along with counseling by the investigator's study dietitians, to help subjects adhere to the limited polyphenolic diet. The trial will initiate with a 3-day food diary to assess background (pre-study) dietary intake followed by counseling to follow a diet relatively low in (poly)phenolic rich-beverages/foods, which will be maintained for the duration of the experiment. After an initial 7 day run-in period on the limited polyphenolic diet, subjects will be randomized to 1 of 2 treatment sequences. Treatment codes will be maintained by the principal investigator/study physician. All subjects will receive both treatments, once each on 2 different occasions and separated by at least 1 week. Red raspberries or placebo will be provided with a standardized meal providing 840 kcal. A low-polyphenol snack will be provided to subjects after their final cognitive assessment.

Each visit will last ~ 9.5 hours and subjects will be required to remain at the Clinical Unit for the duration of the visit. Blood samples will be collected at 0 (fasting) and at 0.5 h, 1 h, 2 h, 4 h, 5 h, 6 h and 7.5 h via a catheter placed on the non-dominant arm by a registered nurse. Cognitive function will be measured at 0 (fasting), 2 h, and 6 h. FMD or NIRS will be conducted at the CNRC or the HNRCA, respectively at 0 (fasting), and at 1 h and 5 h.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 1, 2020
Est. primary completion date February 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 70 Years
Eligibility Inclusion Criteria:

- BMI between 27 and 35 kg/m2 and/or waist circumference (>35 inches for women, >40 inches for men)

- Aged 55-70 years old

- Able to provide informed consent and comply with study procedures

- Willing to maintain stable body weight and follow his/her habitual diet and physical activity patterns throughout the trial.

- Judged by the Investigator to be in general good health on the basis of medical history and screening laboratory tests.

Exclusion Criteria:

- Current smoker and/or marijuana user, past smokers may be allowed in the study if stopped >2 years

- Have a history or presence of atherosclerotic cardiovascular disease, inflammatory disease, diabetes mellitus, or other systemic diseases, psychological or psychiatric disorders

- Have recent surgery or injury to head

- Mini-Mental Status Exam score < 24 or Beck Depression Inventory score > 20

- Taking any medications that would interfere with outcomes of the study (i.e., lipid-lowering medications, anti-inflammatory drugs, and supplements, not including multivitamin/mineral or calcium/Vit D supplements),

- Unstable use of any medication/supplement

- Have a history of cancer in the prior 5 years, except for non-melanoma skin cancer

- Addicted to drugs and/or alcohol (>2 drinks/day)

- Have been exposed to any non-registered drug product within last 30 days.

- Working overnight (e.g. 3rd shift of overnight workers)

- Excessive exercisers or trained athletes

- Have allergies/intolerances to berries.

- Vegetarian/vegan or have extreme dietary habits.

- Excessive coffee/tea drinker

- Actively losing weight/ trying to lose weight (unstable body weight fluctuations of > 5 kg in 3 months)

- Donated blood within last 3 months

- Female who is pregnant, planning to be pregnant, breastfeeding

- Current regular consumption of berries which exceeds > 2 servings per day

- The individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Active breakfast
freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
Control breakfast
Control drink + buttermilk biscuit sandwich

Locations

Country Name City State
United States Clinical Nutrition Research Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Profile of Mood States response between 2 treatments Cognitive assessment tasks will be performed in Profile of Mood States Baseline to 6 hours
Primary Changes in Digit Symbol Coding response between 2 treatments Cognitive assessment tasks will be performed in Digit Symbol Coding Baseline to 6 hours
Primary Changes in Hopkins Verbal Learning Test response between 2 treatments Cognitive assessment tasks will be performed in Hopkins Verbal Learning Test Baseline to 6 hours
Primary Changes in CANTAB- paired-associates-learning response between 2 treatments Cognitive assessment tasks will be performed in CANTAB- paired-associates-learning Baseline to 6 hours
Primary Changes in CANTAB- rapid-visual-information-processing response between 2 treatments Cognitive assessment tasks will be performed in CANTAB- rapid-visual-information-processing Baseline to 6 hours
Primary Changes in CANTAB- spatial-working-memory response between 2 treatments Cognitive assessment tasks will be performed in CANTAB- spatial-working-memory Baseline to 6 hours
Secondary Changes in Psychomotor function between 2 treatments Psychomotor function will be measured with the Grooved Pegboard Baseline to 6 hours
Secondary Changes in postprandial endothelial function between 2 treatments Vascular Assessments will be measured with Flow mediated vasodilation (FMD) Baseline to 5 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1